PALM SPRINGS, Calif., Sept. 2 /PRNewswire/ -- Scientists at Elan Vital Pharmaceuticals announce anti-aging technology applications to a new product, De-Nouveau. De-Nouveau utilizes the Nobel Prize-winning discovery of the enzyme telomerase to change the anti-aging product market.
SAN DIEGO, Sept. 2 /PRNewswire/ -- Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog, and insulin lispro, the active ingredient in Humalog.
TORONTO, Sept. 2 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ROCKVILLE, Md.--(BUSINESS WIRE)--Sep 2, 2010 - RegeneRx Biopharmaceuticals, Inc. today announced that R. Don Elsey has been appointed to the Company's board of directors, effective September 1. Mr. Elsey will serve on the compensation and audit committees of the board of directors.
ROCKVILLE, Md.--(BUSINESS WIRE)--Sep 1, 2010 - Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH), for advanced development of the company's third generation anthrax vaccine candidate.
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Sep 1, 2010 - Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden.
HORSHAM, Pa., Sept. 1 /PRNewswire/ -- World-renowned golf champion and prostate cancer survivor Arnold Palmer has teamed up with Centocor Ortho Biotech Inc. and the non-profit organization Us TOO International Prostate Cancer Education & Support Network to launch My Prostate Cancer Roadmap (www.myprostatecancerroadmap.com), an educational program that provides resources and information specific to advanced prostate cancer patients and those who love them.
OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010/PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Stephen A. Stamp to the company's Board as an independent Non-Executive Director.
LEUVEN, Belgium, September 1, 2010/PRNewswire-FirstCall/ -- ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.
POMPEY, France, September 1, 2010/PRNewswire/ -- Novasep, a leading supplier of manufacturing solutions to the life science industries, announces the appointment of Bernard Dubois as Chairman of its supervisory board. Bernard Dubois replaces Pietro Stefanutti, who decided to allocate most of his time to personal activities.
FORT WORTH, Texas, Sept. 1, 2010 (THE TELEGRAM) - Texas is awarding $2 million from its Emerging Technology Fund to a small Fort Worth company that’s developing medications designed to eliminate life-threatening toxins in patients with kidney disease.
SYDNEY, Australia and BEDMINSTER, N.J., Sept. 1 /PRNewswire-FirstCall/ -- QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.
NEW YORK, Sept. 1, 2010--Standard & Poor's Ratings Services said today that Allergan Inc.'s (A+/Stable/A-1) $610 million-$615 million payment to the U.S. Department of Justice will not affect our ratings or outlook on the company. Allergan agreed to settle the ongoing government investigation regarding the off-label use of Botox for certain therapeutic indications over 2000-2005.
ZURICH, Sept. 1, 2010-Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas (Roflumilast) in Oranienburg today, making Germany the first country to market the medicine. Daxas is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that was developed by Nycomed to treat the progressive, life-threatening lung disease COPD.
ROCKVILLE, Md., Sept. 1, 2010 - FDA reminded healthcare professionals of an increased mortality risk associated with the use of the intravenous antibacterial Tygacil (tigecycline) compared to that of other drugs used to treat a variety of serious infections.
YOKOHAMA, Japan, September 1, 2010/PRNewswire/ -- ReproCELL, Inc. is pleased to announce a new line of products to be launched in the autumn of 2010, offering neuronal cells derived from human iPS (induced pluripotent stem) cells.
CASTRES, France, September 1, 2010/PRNewswire/ -- During its first meeting, the Board of Directors of Pierre Fabre SA chaired by Mr. Pierre Fabre appointed Olivier BOHUON as the company's Chief Executive Officer.
|
